Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin: 2010-2025

Historic EBT Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to -50.46%.

  • Vanda Pharmaceuticals' EBT Margin fell 3736.00% to -50.46% in Q3 2025 from the same period last year, while for Sep 2025 it was -50.52%, marking a year-over-year decrease of 4105.00%. This contributed to the annual value of -11.53% for FY2024, which is 1482.00% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' EBT Margin stood at -50.46%, which was up 23.93% from -66.34% recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBT Margin registered a high of 18.56% during Q2 2021, and its lowest value of -74.67% during Q1 2025.
  • For the 3-year period, Vanda Pharmaceuticals' EBT Margin averaged around -20.64%, with its median value being -10.93% (2024).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 2,141bps in 2023, then crashed by 6,485bps in 2025.
  • Quarterly analysis of 5 years shows Vanda Pharmaceuticals' EBT Margin stood at 12.66% in 2021, then spiked by 225bps to 14.91% in 2022, then slumped by 1,858bps to -3.67% in 2023, then crashed by 855bps to -12.22% in 2024, then crashed by 3,736bps to -50.46% in 2025.
  • Its last three reported values are -50.46% in Q3 2025, -66.34% for Q2 2025, and -74.67% during Q1 2025.